

ASX ANNOUNCEMENT

29 January 2020

APPENDIX 3B NEW ISSUE

Attached is an Appendix 3B in relation to the issue of 2,100,000 Convertible Notes at \$1.00 per note raising \$2.1 million as outlined in the announcement to the market by the Company earlier today titled "Amani Gold raises \$2.1M via a Convertible Note and a further \$3.0M via a Placement".

Nick Harding Company Secretary **Amani Gold Limited**

ABN: 14 113 517 203

CORPORATE DETAILS

ASX Code: ANL

DIRECTORS

KLAUS ECKHOF

Chairman

SIK LAP CHAN Managing Director

and CEO

GRANT THOMAS

Technical Director

QIUMING YU
Executive Director

ANTONY TRUELOVE

Non-Executive Director

NICK HARDING

Company Secretary

CONTACT

Suite 6, 149 Brebner Drive West Lakes SA 5021

1300 258 985

info@amanigold.com

amanigold.com

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

| Name | of entity | |
|------|---|--|
| AMA | ANI GOLD LIMITED | |
| ABN | | |
| 14 1 | .13 517 203 | |
| We (| the entity) give ASX the following | information. |
| _ | t 1 - All issues nust complete the relevant sections (attach | sheets if there is not enough space). |
| 1 | *Class of *securities issued or to be issued | Convertible Note |
| 2 | Number of *securities issued or | 2 100 000 convertible notes |
| 2 | to be issued (if known) or maximum number which may be issued | 2,100,000 convertible notes |
| 0 | D : 1 1 | |
| 3 | Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price | Each convertible note entitles the holder to receive one ordinary share upon the conversion of the convertible note at a conversion price of \$0.003 per note before the expiry date of 24 January 2022. |

and dates for conversion)

Do the *securities rank equally in all respects from the +issue date with an existing +class of quoted *securities?

No. Upon exercise of the convertible notes, shares issued will rank equally with ordinary shares on issue.

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration \$1.00 per convertible note

Purpose of the issue 6 (If issued as consideration for the acquisition of assets, clearly identify those assets)

Funds raised will be used to advance the Giro Gold Project in the DRC including diamond core and RC drilling programs, regional exploration, resource estimate upgrade for the Kebigada deposit, mining studies and for general working capital purposes.

Is the entity an *eligible entity 6a that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

6с Number of *securities issued without security holder approval under rule 7.1

Number of *securities issued 6d with security holder approval under rule 7.1A

N/A

N/A

700,000,000

N/A

04/03/2013 Appendix 3B Page 2

⁺ See chapter 19 for defined terms.

| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | | | |
|----|---|---------------------------------|-----------------|------|----------|
| | | | | | |
| 6f | Number of *securities issued under an exception in rule 7.2 | N/A | | | |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | N/A | | | |
| 61 | 701 | | | | |
| 6h | If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | | | |
| | | | | | |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | Rule 7.1 220,317, Rule 7.1A N/A | .456 | | |
| | | | | | |
| 7 | *Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 29 January 2020 | | | |
| | | | | | |
| | | Number | +Class | | |
| 8 | Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable) | 6,135,449,712 | Fully shares | paid | ordinary |
| | | | | | |

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

| Name la ser | +Cl |
|-------------|--|
| Number | +Class |
| 7,500,000 | Unlisted Options exercisable at \$0.03 |
| | each on or before 31 December 2020. |
| 7,500,000 | Unlisted Options exercisable at \$0.04 |
| | each on or before 31 December 2020. |
| 7,500,000 | Unlisted Options exercisable at \$0.05 |
| | each on or before 31 December 2020. |
| 40,000,000 | Unlisted Options exercisable at \$0.0075 |
| ,,. | each on or before 27 May 2022. |
| 40,000,000 | Unlisted Options exercisable at \$0.01 |
| 40,000,000 | each on or before 27 May 2022. |
| 40 000 000 | • |
| 40,000,000 | Unlisted Options exercisable at \$0.0125 |
| | each on or before 27 May 2022. |
| 12,000,000 | Unlisted Options exercisable at \$0.0075 |
| | each on or before 15 January 2023. |
| 12,000,000 | Unlisted Options exercisable at \$0.01 |
| | each on or before 15 January 2023. |
| 12,000,000 | Unlisted Options exercisable at \$0.0125 |
| | each on or before 15 January 2023. |
| | • |
| 20,000,000 | Performance Rights at \$0.02 expiring 31 |
| 20,000,000 | December 2020. |
| 20,000,000 | Performance Rights at \$0.04 expiring 31 |
| 20,000,000 | |
| 20 000 000 | December 2020. |
| 20,000,000 | Performance Rights at \$0.06 expiring 31 |
| | December 2020. |
| 229,000,000 | Performance Rights at \$0.0075 expiring |
| | 27 May 2022. |
| 229,000,000 | Performance Rights at \$0.01 expiring 27 |
| | May 2022. |
| 229,000,000 | Performance Rights at \$0.0125 expiring |
| | 27 May 2022. |
| 10,000,000 | Performance Rights at \$0.0075 expiring |
| , , | 31 December 2021. |
| 10,000,000 | Performance Rights at \$0.01 expiring 31 |
| 10,000,000 | December 2021. |
| 10,000,000 | Performance Rights at \$0.0125 expiring |
| 10,000,000 | 31 December 2021. |
| 110 000 000 | |
| 116,666,666 | Performance Rights at \$0.0075 expiring |
| 440 000 555 | 11 November 2022. |
| 116,666,666 | Performance Rights at \$0.01 expiring 11 |
| | November 2022. |
| 116,666,666 | Performance Rights at \$0.0125 expiring |
| | 11 November 2022. |
| | |
| 2,100,000 | Convertible Notes at \$0.003 expiring 24 |
| | January 2022. |
| | · |
| L | |

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | N/A |
|------|--|-----|
| | | |
| Part | 2 - Pro rata issue | |
| 11 | Is security holder approval required? | |
| 12 | Is the issue renounceable or non-renounceable? | |
| 13 | Ratio in which the ⁺ securities will be offered | |
| 14 | ⁺ Class of ⁺ securities to which the offer relates | |
| 15 | ⁺ Record date to determine entitlements | |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
| 17 | Policy for deciding entitlements in relation to fractions | |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents | |
| | Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | |
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |

| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | |
|----|---|--|
| 25 | If the issue is contingent on security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |
| | | |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? | |
| 22 | . | |
| 33 | ⁺ Issue date | |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (tick one)
- (a) \bigcirc Securities described in Part 1

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

| (b) | | d of the escrowed period, partly paid securities that become fully paid n restriction ends, securities issued on expiry or conversion of convertible |
|------------------|---|---|
| Entit | ies that have ticked box 34(a) | |
| Addi | tional securities forming a new o | class of securities |
| Tick to łocum | o indicate you are providing the informati ents | on or |
| 35 | | securities, the names of the 20 largest holders of the number and percentage of additional *securities |
| 36 | 1 1 | securities, a distribution schedule of the additional mber of holders in the categories |
| 37 | A copy of any trust deed for the | ne additional ⁺ securities |
| Entit | ies that have ticked box 34(b) | |
| 38 | Number of *securities for which *quotation is sought | |
| 39 | ⁺ Class of ⁺ securities for which quotation is sought | |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? | |
| | If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment | |
| | the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | |

| 41 | Reason for request for quotation now | | |
|----|---|--------|--------|
| | Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another *security, clearly identify that other *security) | | |
| | | | |
| | | Number | +Class |

⁴² Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

| Number | +Class |
|--------|--------|
| | |
| | |
| | |
| | |
| | |
| | |

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

| Sign here: | (Company secretary) | 29 January 2020 Date: |
|-------------|---------------------|--------------------------|
| Print name: | Nick Harding | |
| | | |

Andbud.

04/03/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | |
|---|---------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue | 1,846,363,747 | |
| Add the following: | | |
| Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2 | 1,843,863,747 | |
| Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval | 2,445,222,218 | |
| Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period | Nil | |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period | Nil | |
| "A" | 6,135,449,712 | |

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | |
|---|---|
| "B" | 0.15 |
| | [Note: this value cannot be changed] |
| Multiply "A" by 0.15 | 920,317,456 |
| Step 3: Calculate "C", the amount of that has already been used | of placement capacity under rule 7.1 |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued: | 700,000,000 |
| • Under an exception in rule 7.2 | |
| • Under rule 7.1A | |
| With security holder approval under rule 7.1 or rule 7.4 | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | |
| "C" | 700,000,000 |
| Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1 | B"] to calculate remaining |
| "A" x 0.15 | 920,317,456 |
| Note: number must be same as shown in Step 2 | |
| Subtract "C" | 700,000,000 |
| Note: number must be same as shown in Step 3 | |
| <i>Total</i> ["A" x 0.15] – "C" | 220,317,456 |
| | [Note: this is the remaining placement capacity under rule 7.1] |

04/03/2013 Appendix 3B Page 11

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | |
|--|------------------------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| "A" N/A | | |
| Note: number must be same as shown in Step 1 of Part 1 | | |
| Step 2: Calculate 10% of "A" | | |
| "D" | 0.10 | |
| | Note: this value cannot be changed | |
| Multiply "A" by 0.10 | N/A | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | N/A | |
| Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | | |
| "E" | N/A | |

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | |
|---|--|
| "A" x 0.10 | N/A |
| Note: number must be same as shown in Step 2 | |
| Subtract "E" | - |
| Note: number must be same as shown in Step 3 | |
| Total ["A" x 0.10] – "E" | N/A |
| | Note: this is the remaining placement capacity under rule 7.1A |

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.